Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition.
Annu Rev Med
; 72: 447-458, 2021 01 27.
Article
en En
| MEDLINE
| ID: mdl-33234004
ABSTRACT
Statins, ezetimibe, and PCSK9 inhibitors are currently the standard of care for the prevention and treatment of coronary artery disease. Despite their widespread use, coronary artery disease remains the leading cause of death worldwide, a fact that pleads for the development of new protective therapies. In no small part due to advances in the field of human genetics, many new therapies targeting various lipid traits or inflammation have recently received approval from regulatory agencies such as the US Food and Drug Administration or fared favorably in clinical trials. This wave of new therapies promises to transform the care of patients at risk for life-threatening coronary events.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Enfermedad de la Arteria Coronaria
/
Inhibidores de Hidroximetilglutaril-CoA Reductasas
/
Ezetimiba
/
Inhibidores de PCSK9
Límite:
Humans
Idioma:
En
Revista:
Annu Rev Med
Año:
2021
Tipo del documento:
Article